Regulatory approval is not market access. Across Asia-Pacific, the gap between approval and reimbursement ranges from two months to well over a year, and on our numbers it can erase up to half of a life science exit case. Why most models miss it, and how to fix that.

Biogen, Merck, and Takeda didn't get their market sizing wrong — the ground moved under them. Why TAM/SAM/SOM models need to be rebuilt on every clinical and commercial trigger, not just at the next fundraising round.

Financial models in life science M&A are precise — but often built on oversimplified biological assumptions. This article examines how therapeutic-area variability, translational fragility, and CMC complexity materially impact valuation, timelines, and exit outcomes.

Scientific risk in life sciences does not disappear after venture capital exits — it migrates into the structural mechanics of scale, manufacturing, and platform dependency. As private equity activity rebounds, investors increasingly find that value creation hinges not on whether the science works, but on the conditions under which it continues to work at scale. This article explores why scientific diligence must evolve from validation into strategic risk mapping that directly informs underwriting, value-creation planning, and exit narratives.

An investor-focused analysis of how venture capital in life sciences and healthcare recalibrated in 2025, examining regional differences across the US, Europe, and Asia — and what these shifts mean for sourcing, diligence, and portfolio construction as the market moves into 2026..

From launching targeted service lines to representing Biorizon Consulting on the international stage, our first year has been one of growth, collaboration, and strategic impact. Here’s a look back at the milestones that shaped our journey — and where we’re heading next.

Dr Laura Marie Zimmermann at the Biorizon Consulting booth during Transforming Science Day at EMBL Heidelberg — the consultancy’s first official booth in Europe, showcasing its work at the interface of preclinical strategy, innovation, and cross-continental collaboration.

AI is redefining the life sciences industry. Whether it’s accelerating drug discovery, revolutionising diagnostics, or enabling precision medicine, AI is changing how we approach healthcare and biotechnology. At Biorizon Consulting, we help organisations navigate this dynamic landscape by providing strategic guidance and practical solutions, ensuring innovation aligns with both opportunity and responsibility.

Driving Innovation in Preclinical Research: Sucessfull Collaboration with Boehringer Ingelheim

We Attend the Week of Technology and Innovation at Marina Bay Sands, October 2024

Selangor Business Summit in Kuala Lumpur October 2024

Exploring the Future of Labs at Thailand LAB 2024: Embracing Digitalisation and Innovation!

Innovation Meets Expertise: Transforming Ideas into Life Science Solutions.

Biorizon Consulting at Asia Pacific's Leading Life Science Conferences